Envisagenics - discovering cures for diseases
Envisagenics is a New York-based company that integrates RNA splicing analytics with artificial intelligence (AI) for drug discovery.
Their mission is to reduce the complexity of biomedical data in order to accelerate the development of innovative therapeutic solutions.
The team at Envisagenics uses the company's breakthrough technology to identify disease-causing splicing errors, find the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Envisagenics' in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.
Envisagenics was one of the four winners of the recent Innovate.AI global startup competition, which was held by M12 (formerly Microsoft Ventures), Madrona Venture Group, Notion Capital, and Vertex Ventures Israel to further the development of AI to solve problems and improve people’s lives. They also received a $1 million investment award from M12 and Madrona Venture Group.